SCHEDULE: FMR LLC Boosts Stake in Ocular Therapeutix to 15%

FMR LLC and Abigail P. Johnson have reported an aggregate beneficial ownership of 15.0% of Ocular Therapeutix Inc.'s common stock as of September 30, 2025.

Summary

• FMR LLC and Abigail P. Johnson collectively beneficially own 31,785,633.58 shares of OCULAR THERAPEUTIX INC common stock.
• This represents 15.0% of the total outstanding common stock of OCULAR THERAPEUTIX INC.
• FMR LLC holds sole voting power over 31,779,018.00 shares and sole dispositive power over 31,785,633.58 shares.
• Abigail P. Johnson holds sole dispositive power over 31,785,633.58 shares.
• Fidelity Growth Company Commingled Pool, an entity associated with FMR LLC, holds 12,562,705.00 shares, representing 5.9% of the total outstanding common stock as of September 30, 2025.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
• This filing is an Amendment No. 1 to a previous Schedule 13G.

Sentiment

Score: 7

Explanation: The filing indicates a significant and stable institutional ownership by FMR LLC, a major asset manager, which is generally viewed positively as a vote of confidence in the company. The ownership is stated to be for ordinary course investment, not control-seeking.

Positives

• A significant institutional investor, FMR LLC (Fidelity), maintains a substantial 15.0% stake in Ocular Therapeutix Inc., indicating continued confidence in the company.
• The beneficial ownership is held in the ordinary course of business, not for the purpose of influencing or changing control, suggesting a passive investment strategy.

Risks

• While the filing states the securities were not acquired for the purpose of changing or influencing control, a large institutional stake could still exert indirect influence on management decisions or strategic direction.
• The concentration of ownership by a single entity (FMR LLC and its affiliates) could lead to significant share price volatility if FMR LLC were to substantially alter its position.

Future Outlook

NA

Industry Context

This filing indicates continued institutional interest in Ocular Therapeutix Inc., a company likely operating in the biotechnology or pharmaceutical sector, given its name. Large stakes by major asset managers like FMR LLC are common across various industries, reflecting investment strategies rather than specific industry trends.

Stakeholder Impact

• Shareholders: The continued significant stake by a major institutional investor like FMR LLC may provide a sense of stability and confidence, potentially attracting other investors.
• Management: While FMR LLC states its investment is passive, its large stake means management will likely be mindful of FMR LLC's position and potential influence.

Key Dates

Recommendation

The filing is a routine disclosure of beneficial ownership by a major institutional investor, FMR LLC, maintaining a significant 15.0% stake in Ocular Therapeutix Inc. This indicates continued confidence from a large asset manager, which is generally a positive signal. However, it does not provide new operational or financial performance data to warrant a change in investment thesis. The investment is stated to be passive, not for control, suggesting no immediate strategic shifts are anticipated due to this ownership. Therefore, a 'hold' recommendation is appropriate, acknowledging the stable institutional backing without new catalysts for 'buy' or 'sell'.

Keywords

Ocular Therapeutix, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Fidelity, Biotechnology, Pharmaceuticals